Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers
- 31 December 2004
- Vol. 25 (12), 2087-2097
- https://doi.org/10.1016/j.peptides.2004.08.018
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsSeminars in Nuclear Medicine, 2002
- Neuroendocrine tumor targeting: Study of novel gallium‐labeled somatostatin radiopeptides in a rat pancreatic tumor modelInternational Journal of Cancer, 2002
- Differential Expression of Somatostatin Receptors in MedulloblastomaJournal of Neuro-Oncology, 2001
- 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivativesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- High Expression of Somatostatin Receptor Subtype 2 (sst2) in Medulloblastoma: Implications for Diagnosis and TherapyPediatric Research, 1999
- A Microplate Binding Assay for the Somatostatin Type-2 Receptor (SSTR2)Journal of Receptors and Signal Transduction, 1999
- Human pancreatic cancer cell lines do not express receptors for somatostatinBritish Journal of Cancer, 1992
- Binding and internalization of somatostatin, insulin, and glucagon by cultured rat islet cells.Journal of Clinical Investigation, 1989
- The preparation of astatine labelled proteinsThe International Journal of Applied Radiation and Isotopes, 1975